Pyramid Studio
A new chapter of therapeutic innovation
Pyramid studio embodies a new way of leading therapeutic innovation. It is a First-of-its-Kind, entrepreneurial-type, venture builder exclusively dedicated to fuel the pipeline of pharmaceutical companies.
Highlyseasoned entrepreneur team with a successfultrackrecord in Pharma & Biotech
Who we are
We are a team of passionate and seasoned healthcare entrepreneurs and industry leaders with longstanding experience across the entire pharmaceutical industry (biotech, pharma, venture capital). We built biotech companies, we worked in Tech Transfer Offices, we performed drug discovery and developed drugs across all stages of development. Our goal is to simplify the innovation value chain to deliver faster therapies to patients.
What we do
We are bridging the gap between science and value. We scout, de-risk and advance breakthrough innovations from Europe’s top academic teams at the door of the clinic for our Pharma partners. We provide them with high-value assets focusing exclusively on Immunology & Inflammation (excluding oncology), neurological and rare diseases. Our team brings deep scientific expertise, hands-on experience, and a vast network in these fields.
We Scout
…groundbreaking innovations using a unique streamlined process relying on our innovative business model
We build up
…strategic R&D roadmaps to transform groundbreaking discoveries into valuable, patient-centered assets
We collaborate
… with a broad network of KOLs, experts, CROs to challenge our plans and achieve operational excellence
We deliver
… to our partners robust, near-to-the-clinic assets adding value to their drug portfolio
Why
Immuno-Inflammation neurological and rare diseases
Public health burden
We are dedicated to tackling some of the most challenging health conditions affecting millions worldwide. Immuno-inflammatory (I&I), neurological (CNS), and rare diseases not only impact the lives of patients but also pose significant challenges to healthcare systems globally.
Facts & Figures
Immuno-inflammatory diseases…
…such as rheumatoid arthritis, lupus, and inflammatory bowel diseases affect millions more, often leading to chronic pain, disability, and premature death. In the U.S., the economic burden of I&I diseases is estimated at $100 billion annually. I&I diseases often require complex, lifelong management, and while there are treatments, they are not always effective.
Neurological diseases…
…like Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis affect over 1 billion people globally. They can affect memory, speech, and motor skills, often leading to a gradual loss of autonomy. Their global economic cost is estimated at $2 trillion. Many CNS diseases still lack disease-modifying treatments as for example only 1 in 5 patients with multiple sclerosis are treated with FDA-approved disease-modifying therapies, showing the gap in effective treatments.
Rare diseases…
…collectively impact an estimated 350 million people worldwide with over 7,000 identified rare diseases. Currently, only about 10% of rare diseases have approved treatments.
Hope for the Future
Over the last decade, advancements in genetic therapies, biologics, and precision medicine have shown promise giving hope to patients. Pyramid Studio accompanies this movement by offering a new model of therapeutic innovation. We build drug-centric innovation hubs gathering scientists, entrepreneurs and pharmaceutical companies to better and faster bridge the gap from science to therapies for patients.
80
Types of autoimmune
diseases
1
people out of 12 worldwide affected by autoimmune diseases
3nd
cause of morbidity
in the world
$120bn
of annual expenses in the US for autoimmune diseases
What makes us different
We offer a new business model that streamlines the traditional innovation value chain, speeding up the integration of new drugs in our partners portfolio, and the delivery of breakthrough medicines to patients.
Pyramid Studio serves as a one-stop innovation hub embedding the capital and market vision of our partners (Pharma & Biotech companies) with top European academic science. Pyramid provides the other essentials: ability to turn discoveries into useful and valuable drugs, capital efficiency, agility and entrepreneurial mindset.
A purpose-driven model
We act exclusively to fuel the pipeline of Pharmaceutical / large Biotech companies.
A focus on Immuno-inflammation, CNS and rare diseases
While our team has accumulated a solid track record in this field, it is marked by persistent high unmet medical needs and unresolved challenges.
A unique business model
We draw interest from pharmaceutical companies by operating as a corporate venture fund.
A fair value distribution
We attract scientists who are looking for a quicker path to reach patients and a more equitable way of sharing value.
Which
benefits to our partners
We offer to our partners an innovative, tailored and effective alternative to traditional external innovation channels e.g. licensing and M&A.
- An access to ground-breaking discoveries stemming out from top-notched science
- An innovation hub structured around industry-driven relationships
- 5 to 10 times cheaper near-to-clinic assets with the potential of breakthrough medicine
- Reduced R&D-related financial burden thanks to a plug-and-play corporate venture firm model
#1
Integrated off-P&L venture builder
#2
Highly skilled & experienced team with proven records
#3
Tailored & Flexible R&D capabilities by-passing competition
#4
Assets acquisition 10-times cheaper than preclinical-stage M&A deals
